Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.095 -0.065 (-3.01%)

Streaming Delayed Price Updated: 11:40 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio ↗

April 06, 2023

Neither stock is a good choice for those who can't handle a lot of risk.

Via The Motley Fool

Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future? ↗

April 03, 2023

EDIT-301 had positive clinical results in treating sickle cell disease, but the potential payoff is still years in the future.

Via The Motley Fool

2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It ↗

March 30, 2023

Editas Medicine is a high-risk stock with the potential of a big reward.

Via The Motley Fool

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗

March 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

Via InvestorPlace

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗

March 25, 2023

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

Via InvestorPlace

Editas Medicine Earnings Preview ↗

February 21, 2023

Via Benzinga

Top CRISPR Stocks ↗

February 11, 2023

CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.

Via Talk Markets

Why Editas Medicine Stock Charged Higher in January ↗

February 02, 2023

The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.

Via The Motley Fool

Expert Ratings for Editas Medicine ↗

February 01, 2023

Via Benzinga

Thinking of Buying Biotech Stocks? Do These 3 Things First ↗

March 22, 2023

It's better to plan ahead than to get caught by surprise.

Via The Motley Fool

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer

March 08, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

February 22, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

These 2 Biotech Stocks Could Soar in the Next Bull Market ↗

February 17, 2023

They're both at the cutting edge of gene-editing technology.

Via The Motley Fool

Why Shares of Editas Medicine Jumped This Week ↗

January 26, 2023

It's been a seesaw month for the clinical-stage gene-editing biotech.

Via The Motley Fool

Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies ↗

January 19, 2023

Via Benzinga

Analyst Expectations for Editas Medicine's Future ↗

January 10, 2023

Via Benzinga

Why Editas Medicine Stock Is Sliding Today ↗

January 09, 2023

The gene-editing pioneer announced a big shake-up with its research and development programs.

Via The Motley Fool

Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023? ↗

February 16, 2023

Which of these rebounding biotech stocks is the better buy right now?

Via The Motley Fool

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update

February 15, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

3 No-Brainer Stocks to Buy Right Now for Less Than $25 ↗

February 04, 2023

All three healthcare stocks are showing solid long-term potential.

Via The Motley Fool

Why Editas Medicine's Shares Jumped This Week ↗

February 03, 2023

The gene-editing biotech's shares have had a strong two-week run.

Via The Motley Fool

Is Editas Medicine Stock a Buy Now? ↗

February 03, 2023

Layoffs and a thin clinical-stage pipeline aren't very encouraging.

Via The Motley Fool

3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later ↗

February 02, 2023

CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.

Via InvestorPlace

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock ↗

February 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗

February 01, 2023

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

January 25, 2023

Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.

Via MarketBeat

Topics Workforce

Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies

January 19, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years ↗

January 18, 2023

CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years.

Via InvestorPlace

Editas Medicine Announces Strategic Updates and Portfolio Reprioritization

January 09, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.